Higher disease activity of inflammatory bowel disease predisposes to Clostridioides difficile infection

被引:0
|
作者
Vitikainen, Krista [1 ]
Kase, Merit [2 ]
Meriranta, Leo [2 ]
Molander, Pauliina [3 ,4 ]
af Bjorkesten, Clas-Goran [3 ,4 ]
Anttila, Veli-Jukka [4 ,5 ]
Arkkila, Perttu [3 ,4 ]
机构
[1] HUS Helsinki Univ Hosp, Haartmaninkatu 4,POB 340, Helsinki 00029, Finland
[2] HUS Helsinki Univ Hosp, Helsinki, Finland
[3] HUS Helsinki Univ, Abdominal Ctr, Gastroenterol, Helsinki, Finland
[4] Univ Helsinki, Helsinki, Finland
[5] Helsinki Univ Hosp, Dept Infect Dis, Helsinki, Finland
关键词
<italic>Clostridioides difficile</italic>; gastrointestinal infections; inflammatory bowel disease; HEALTH-CARE EPIDEMIOLOGY; HOSPITALIZED-PATIENTS; AMERICA IDSA; GUIDELINES; MANAGEMENT; IMPACT; RISK; DIAGNOSIS; COLECTOMY; COLITIS;
D O I
10.1177/17562848251318292
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Clostridioides difficile infection (CDI) is a clinical challenge associated with poor outcomes in patients with inflammatory bowel disease (IBD).Objectives: To identify clinical risk factors for CDI and its recurrence among patients with IBD.Design: Case-control cohort study of IBD patients with and without episodes of CDI.Methods: A case-control study of 279 IBD patients with CDI. Medical history and IBD-related symptoms 3 months preceding a toxin-positive CDI were recorded and compared with age- and sex-matched IBD patients without CDI. Outcomes of CDI in IBD patients were recorded 2-6 months after CDI.Results: Based on clinical symptoms and fecal calprotectin levels, IBD is active before CDI. Recently diagnosed IBD seemed to increase the risk for CDI. Corticosteroid usage frequently preceded CDI episodes. Advanced therapies were not associated with CDI. Antibiotic intake was not registered before CDI in 30% of the episodes. Recurrent CDI (rCDI) occurred in 30% (84/279) of IBD-CDI patients and 67% (90/135) of those episodes were registered within 90 days from the preceding episode. Most (79%) rCDI patients had ulcerative colitis (UC). CDI could complicate underlying IBD by increasing the need for escalation in IBD-related medical therapy and leading to hospitalization but it did not seem to increase the risk of colectomy.Conclusion: The major risk factors associated with CDI in IBD patients were IBD activity before infection, UC and colonic Crohn's disease, short duration of IBD, corticosteroid usage, and hospitalization. Patients with active IBD and a shorter disease duration may benefit from more frequent follow-ups in the early stages, as they appear to be at higher risk of developing CDI.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Clostridioides difficile Infection in Children With Inflammatory Bowel Disease
    Chandrakumar, Abin
    Zohni, Hussein
    El-Matary, Wael
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (11) : 1700 - 1706
  • [2] Clostridioides difficile Infection in Pediatric Inflammatory Bowel Disease
    Reasoner S.A.
    Nicholson M.R.
    Current Gastroenterology Reports, 2023, 25 (11) : 316 - 322
  • [3] The interplay of Clostridioides difficile infection and inflammatory bowel disease
    Sehgal, Kanika
    Yadav, Devvrat
    Khanna, Sahil
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [4] Management of Clostridioides difficile infection in patients with inflammatory bowel disease
    Khanna, Sahil
    INTESTINAL RESEARCH, 2021, 19 (03) : 265 - 274
  • [5] Risk of Clostridioides difficile infection in patients with inflammatory bowel disease
    Martinez Lozano, H.
    Saralegui Gonzalez, P.
    Fueyo Pelaez, P. R.
    Garcia Garcia, A.
    Miranda-Bautista, J.
    Reigadas Ramirez, E.
    Alcala Hernandez, L.
    Munoz Garcia, P.
    Marin-Jimenez, I.
    Menchen, L.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I2044 - I2044
  • [6] Clostridioides difficile infection in inflammatory bowel disease: a clinical review
    Tang, Mengjun
    Wang, Chunhua
    Xia, Ying
    Tang, Jian
    Wang, Jiao
    Shen, Liang
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (05) : 297 - 306
  • [7] Fidaxomicin treatment for Clostridioides difficile infection in patients with inflammatory bowel disease
    Koop, Andree H.
    Travers, Paul M.
    Khanna, Sahil
    Pardi, Darrell S.
    Farraye, Francis A.
    Hashash, Jana G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 (11) : 1910 - 1916
  • [8] Fidaxomicin for Treatment of Clostridioides difficile Infection in Patients With Inflammatory Bowel Disease
    Travers, Paul
    Koop, Andree H.
    Khanna, Sahil
    Pardi, Darrell S.
    Farraye, Francis A.
    Hashash, Jana G.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S598 - S599
  • [9] Prevalence and Inpatient Outcomes of Clostridioides difficile Infection in Inflammatory Bowel Disease
    Uddin, Anwar
    Dave, Prashil
    Lymberopoulos, Peter
    Ahad, Madia
    Uddin, Rafat
    Uddin, Rahat.
    Ahad, Afgal
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S803 - S803
  • [10] Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease
    Dalal, Rahul S.
    Allegretti, Jessica R.
    CURRENT OPINION IN GASTROENTEROLOGY, 2021, 37 (04) : 336 - 343